Table 2.

Cox proportional hazard models for overall survival (n = 198)

Variables		Multivariate analysis
		HR	95% CI	p Value
Age (years)	≥ 75	1.029	0.708–1.496	0.880
Sex	Male	1.394	1.007–1.929	0.045
ECOG–PS		1.825	1.532–2.174	< 0.001
Clinical stage		1.370	0.716–2.622	0.342
Brain metastases	Yes	1.587	1.119–2.252	0.010
EGFR mutation type	19 del	0.358	0.193–0.665	0.001
	L858R	0.485	0.263–0.895	0.021
Treatmenta	Chemotherapy	0.703	0.477–1.037	0.095
	G1,2 EGFR-TKIb	0.928	0.536–1.607	0.791
	Osimertinib	0.480	0.326–0.707	< 0.001
	ICIc	1.142	0.684–1.907	0.611

HR, hazard ratio; Cl, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; del 19, exon 19 deletion; TKI, tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor

^aDrugs administered throughout the treatment period

^bGefitinib, elrotinib, and afatinib

^cICI monotherapy or ICI + chemotherapy